Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers
- PMID: 37629714
- PMCID: PMC10456451
- DOI: 10.3390/medicina59081424
Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers
Abstract
Hypertrophic cardiomyopathy (HCM) is the most prevalent heritable cardiomyopathy. HCM is considered to be caused by mutations in cardiac sarcomeric protein genes. Recent research suggests that the genetic foundation of HCM is much more complex than originally postulated. The clinical presentations of HCM are very variable. Some mutation carriers remain asymptomatic, while others develop severe HCM, terminal heart failure, or sudden cardiac death. Heterogeneity regarding both genetic mutations and the clinical course of HCM hinders the establishment of universal genotype-phenotype correlations. However, some trends have been identified. The presence of a mutation in some genes encoding sarcomeric proteins is associated with earlier HCM onset, more severe left ventricular hypertrophy, and worse clinical outcomes. There is a diversity in the mechanisms implicated in the pathogenesis of HCM. They may be classified into groups, but they are interrelated. The lack of known supplementary elements that control the progression of HCM indicates that molecular mechanisms that exist between genotype and clinical presentations may be crucial. Secondary molecular changes in pathways implicated in HCM pathogenesis, post-translational protein modifications, and epigenetic factors affect HCM phenotypes. Cardiac loading conditions, exercise, hypertension, diet, alcohol consumption, microbial infection, obstructive sleep apnea, obesity, and environmental factors are non-molecular aspects that change the HCM phenotype. Many mechanisms are implicated in the course of HCM. They are mostly interconnected and contribute to some extent to final outcomes.
Keywords: comorbidities; environment; epigenetics; gene; genetics; genotype; hypertrophic cardiomyopathy; modifier; outcomes; phenotype.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy.Gene. 2016 Feb 15;577(2):227-35. doi: 10.1016/j.gene.2015.11.048. Epub 2015 Dec 2. Gene. 2016. PMID: 26656175
-
Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy.Circulation. 2022 Apr 19;145(16):1238-1253. doi: 10.1161/CIRCULATIONAHA.121.056265. Epub 2022 Apr 6. Circulation. 2022. PMID: 35384713 Free PMC article.
-
The molecular genetic basis for hypertrophic cardiomyopathy.J Mol Cell Cardiol. 2001 Apr;33(4):655-70. doi: 10.1006/jmcc.2001.1340. J Mol Cell Cardiol. 2001. PMID: 11273720 Free PMC article. Review.
-
A novel mutation in the cardiac myosin-binding protein C gene is responsible for hypertrophic cardiomyopathy with severe ventricular hypertrophy and sudden death.Clin Sci (Lond). 2006 Jan;110(1):125-31. doi: 10.1042/CS20050189. Clin Sci (Lond). 2006. PMID: 16181148
-
Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.Clin Res Cardiol. 2018 Jan;107(1):30-41. doi: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24. Clin Res Cardiol. 2018. PMID: 28840316 Review.
Cited by
-
Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy.Biomedicines. 2025 Jul 1;13(7):1619. doi: 10.3390/biomedicines13071619. Biomedicines. 2025. PMID: 40722692 Free PMC article. Review.
-
HCM-Echo-VAR-Ensemble: Deep Ensemble Fusion to Detect Hypertrophic Cardiomyopathy in Echocardiograms.IEEE Open J Eng Med Biol. 2024 Oct 25;6:193-201. doi: 10.1109/OJEMB.2024.3486541. eCollection 2025. IEEE Open J Eng Med Biol. 2024. PMID: 39698121 Free PMC article.
-
Mass Spectrometric ITEM-FOUR Analysis Reveals Coding Single-Nucleotide Polymorphisms in Human Cardiac Troponin T That Evade Detection by Sandwich ELISAs Which Use Monoclonal Antibodies M7 and M11.7 from the Elecsys Troponin T® Assay.Int J Mol Sci. 2025 May 20;26(10):4892. doi: 10.3390/ijms26104892. Int J Mol Sci. 2025. PMID: 40430031 Free PMC article.
-
Patterns of Increased Cardiomyocyte Ploidy in Myocardial Hypertrophy of Various Origins.Bull Exp Biol Med. 2025 Jan;178(3):301-306. doi: 10.1007/s10517-025-06325-x. Epub 2025 Feb 13. Bull Exp Biol Med. 2025. PMID: 39948178
-
The MYH7 c.2770G > A (p.Glu924Lys) mutation exhibits phenotypic heterogeneity in hypertrophic cardiomyopathy (HCM) and restrictive cardiomyopathy (RCM): a case report.BMC Cardiovasc Disord. 2025 Jul 16;25(1):514. doi: 10.1186/s12872-025-04943-x. BMC Cardiovasc Disord. 2025. PMID: 40670969 Free PMC article.
References
-
- Zegkos T., Tziomalos G., Parcharidou D., Ntelios D., Papanastasiou C.A., Karagiannidis E., Gossios T., Rouskas P., Katranas S., Paraskevaidis S., et al. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy. Hell. J. Cardiol. 2022;63:15–21. doi: 10.1016/j.hjc.2021.06.005. - DOI - PubMed
-
- Cao Y., Zhang P.Y. Review of recent advances in the management of hypertrophic cardiomyopathy. Eur. Rev. Med. Pharmacol. Sci. 2017;21:5207–5210. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical